Quoting from ASCO Post, “Amivantamab-vmjw, an EGFR and MET bispecific monoclonal antibody, has demonstrated encouraging long-term benefits and consistent efficacy in patients with advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions, according to data presented by Pilar Garrido, MD, PhD, Associate Professor of Oncology at the Universidad de Alcalá and Head of the Medical Oncology Department at the University Ramón y Cajal Hospital in Madrid, at the European Lung Cancer Congress 2023.

Amivantamab is currently being explored in the phase III -PAPILLON study, which is investigating amivantamab plus chemotherapy vs chemotherapy alone in the front-line EGFR exon 20 insertion NSCLC setting. The outcomes of the PAPILLON study will further elucidate the role of amivantamab in improving the upfront management of patients with advanced NSCLC and EGFR exon 20 insertions, Dr. Garrido concluded.”

Read more at: Ascopost